Gamco Investors INC. ET AL boosted its holdings in shares of Perrigo Company plc (NYSE:PRGO – Free Report) by 26.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,077,785 shares of the company’s stock after buying an additional 222,287 shares during the period. Gamco Investors INC. ET AL’s holdings in Perrigo were worth $15,003,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Perrigo by 7.9% in the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after purchasing an additional 1,101,154 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Perrigo by 2.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock worth $171,367,000 after purchasing an additional 181,828 shares during the last quarter. State Street Corp increased its position in Perrigo by 9.5% in the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after purchasing an additional 637,678 shares during the last quarter. Ion Asset Management Ltd. increased its position in Perrigo by 34.7% in the 2nd quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock worth $102,007,000 after purchasing an additional 983,727 shares during the last quarter. Finally, Cooke & Bieler LP increased its position in Perrigo by 11.6% in the 3rd quarter. Cooke & Bieler LP now owns 3,680,411 shares of the company’s stock worth $81,963,000 after purchasing an additional 381,290 shares during the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.
Perrigo Stock Performance
Shares of NYSE PRGO opened at $10.70 on Tuesday. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -0.82, a P/E/G ratio of 1.24 and a beta of 0.52. The business’s 50-day simple moving average is $10.76 and its 200-day simple moving average is $13.06. Perrigo Company plc has a 52 week low of $9.23 and a 52 week high of $28.43.
Perrigo Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th will be issued a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.8%. Perrigo’s dividend payout ratio is currently -8.85%.
Wall Street Analyst Weigh In
Several research analysts have weighed in on PRGO shares. Canaccord Genuity Group dropped their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.33.
Get Our Latest Stock Analysis on PRGO
Perrigo Profile
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Further Reading
- Five stocks we like better than Perrigo
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
